ClinicalTrials.gov record NCT07850284

SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders

Record copied from ClinicalTrials.gov: Oct 10, 2026AI summaries generated: Oct 10, 2026

SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders

StatusRecruitingThe study is currently enrolling participants. Only the study team can say whether a particular person can join.
Study typeObservationalA study in which researchers do not assign participants to a treatment or other intervention. They observe or measure what happens, which may include study visits, tests, questionnaires or a review of medical records.
Age18 years old and older
SexAll
LocationUnited States
AI summaryWhat this study is about, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

This prospective observational study tests daily text-message symptom monitoring in people with multiple myeloma or AL amyloidosis who are receiving treatment. Participants receive daily SMS prompts and complete questionnaires for three months. The study will measure engagement and acceptability, track automated alerts, and model symptom and quality-of-life over time.

What it is studying. Whether daily SMS-based symptom monitoring is feasible and acceptable for people with multiple myeloma or AL amyloidosis, and whether system-generated alerts identify symptoms that lead to documented clinical actions. It also tracks symptom and quality-of-life patterns and frailty over the three-month study period.

What the researchers hope to learn. Scientifically, the study aims to measure engagement (daily/weekly response rates, uninterrupted participation, completeness), acceptability (CSQ-8), the proportion of alerts that prompt clinical actions, trajectories of symptoms and quality-of-life (PROMIS-29, SF-36), and changes in frailty (IMWG-FI) over three months.

What this study is about

The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.

This study evaluates whether daily SMS-based (text messages) symptom monitoring is feasible and acceptable in patients who are undergoing treatment for multiple myeloma (MM) or systemic light chain amyloidosis (AL), and whether it can help in early identification of symptoms that may require clinical attention.

Interventions being studied

Being studied in this trial does not mean the treatment or procedure is approved or available for this condition.

Other
  • Non-Interventional Study

Eligibility

The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.

Inclusion criteria

  • Age >= 18 years
  • Diagnosis of MM or AL based on IMWG diagnostic criteria
  • Planned to start a new treatment within 14 days (+/-7 days)
  • Able to provide written informed consent

Exclusion criteria

  • Not able to give informed consent

Study description and what participation involves

The registry record has no detailed description beyond the summary above.

AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

Participants are enrolled in a quality-of-life text-message system and will receive daily SMS prompts and complete symptom questionnaires every day for 3 months. The study also collects PROMIS-29 and SF-36 patient-reported surveys from baseline through 3 months and a post-study satisfaction survey (CSQ-8). Responses can generate system alerts that the study will track and that may prompt documented clinical actions (for example: triage calls, provider outreach, medication adjustments, referrals, or unplanned visits). Frailty will be assessed during the study using the International Myeloma Working Group Frailty Index (IMWG-FI).

How the study is structured. This is a prospective observational cohort study (non-interventional). Enrolled participants join a text-message system, receive daily SMS prompts, and complete daily questionnaires for up to three months. The study collects response rates and uninterrupted participation, uses a post-study satisfaction survey (CSQ-8), models PROMIS-29 and SF-36 scores from baseline to three months, assesses frailty with the IMWG-FI, and records whether system-generated alerts result in documented clinical actions.

Questions you could ask

These questions are suggestions for a conversation with the study team or your own clinician, not advice.

  • This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
  • The listed sites are in United States. Is any of them reachable for me, and does the study help with travel?
  • Which of the eligibility criteria would need to be checked with tests before I could join?

More on AL amyloidosis

Clinical trials69 trials listed for AL amyloidosisEvery trial the registry lists for AL amyloidosis, with recruitment status, phase and sites, updated from ClinicalTrials.gov.See all trials →Research updatesWhat changed in AL amyloidosis researchLatest monthly update: September 2026. Includes: Daratumumab alone. New research summarized each month in plain language, with links to every source paper.Read the latest update →

Important dates

Study start
Aug 25, 2026
Primary completion
Aug 25, 2028 (estimated)
Study completion
Aug 25, 2028 (estimated)
Target enrollment
150 participants (estimated)
Last updated on registry
Sep 30, 2026
Data verified
Oct 10, 2026

Sponsor and research team

The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.

Lead sponsor
Mayo Clinic

Central study contact

If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.

Participating sites (1)

  • Mayo Clinic in RochesterRecruiting

    Rochester, Minnesota, 55905 · United States

Terms used on this page · explanations by MedicalUpdates.ai

written informed consent
The process of explaining a study, including its risks and what participation involves, so that a person can decide freely whether to take part. Consent is usually documented in writing, and a participant can choose to leave the study later.
Inclusion Criteria
The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
Exclusion Criteria
The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.

The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.

← Back to clinical trials